Teva and Pfizer Settle Generic Neurontin Litigation

Teva Pharmaceutical Industries Ltd. TEVA announced today that patent litigation with Pfizer Inc. related to generic versions of Pfizer's PFE Neurontin capsules and tablets sold by Teva and its subsidiary IVAX Pharmaceuticals has been dismissed by the United States District Court for the District of New Jersey pursuant to a settlement between the parties, which provides for a full release of Teva and its subsidiaries. The financial terms of the settlement are confidential.